Cargando…
Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer
When treating patients with unresectable stage III non-small-cell lung cancer (NSCLC), those with a good performance status and disease measured within a radical treatment volume should be considered for definitive concurrent chemoradiotherapy (cCRT). This guidance is based on key scientific rationa...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735212/ https://www.ncbi.nlm.nih.gov/pubmed/33293671 http://dx.doi.org/10.1038/s41416-020-01070-6 |